Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec 6;6(12):001310.
doi: 10.12890/2019_001310. eCollection 2019.

Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists

Inês Esteves Cruz  1 , Pedro Ferreira  2 , Raquel Silva  1 , Francisco Silva  1 , Isabel Madruga  1
Affiliations
Case Reports

Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists

Inês Esteves Cruz et al. Eur J Case Rep Intern Med. .

Abstract

Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a direct factor Xa inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a direct Xa inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety.

Learning points: Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT.Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, directed towards preventing thrombosis or its recurrence.A direct factor Xa inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment.

Keywords: Inferior vena cava agenesis; deep vein thrombosis; direct factor Xa inhibitors; rivaroxaban.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interest

Figures

Figure 1
Figure 1
(A) IVC agenesis of the infrarenal segment (CT scan). The IVC is missing (arrow). (B) The corresponding axial image in a normal patient (arrowhead)
Figures 2 and 3
Figures 2 and 3
Superficial varicose veins in both thighs and lower abdomen, showing the presence of collaterals involving the internal saphenous territory
Figures 2 and 3
Figures 2 and 3
Superficial varicose veins in both thighs and lower abdomen, showing the presence of collaterals involving the internal saphenous territory
See this image and copyright information in PMC

References

    1. Gensas C, Pires L, Kruse M, Leiria T, Gomes D, Lima G. Agenesis of the inferior vena cava. Rev Bras Cardiol Invasiva. 2012;20(4):427–430.
    1. Lambert M, Marboeuf P, Midulla M, Trillot N, Beregi JP, Mounier-Vehier C. Inferior vena cava agenesis and deep vein thrombosis: 10 patients and review of the literature. Vasc Med. 2010;15:451–459. - PubMed
    1. Singh S, Bhatt T. Inferior vena cava agenesis: a rare cause of pelvic congestion syndrome. J Clin Diagn Res. 2017;11(3):06–08. - PMC - PubMed
    1. Kalogridaki E, Kanioura E, Mavrigiannaki E, Katralis P, Filippou D, Skandalakis P, et al. Deep vein thrombosis and inferior vena cava agenesis. J Pediatr Surg Case Rep. 2018;34:1–3.
    1. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–1222. - PubMed

Publication types

LinkOut - more resources